TrialThe lancet. HIV2023

Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.

Raphael J Landovitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.